Search Results

Revance to Present New DAXXIFY[R] Data at the American Academy of Neurology 2024 Annual Meeting.

• Source: Business Wire. 2024.

Record details

Revance Receives Permanent J-Code for DAXXIFY[R] and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology[R].

• Source: Business Wire. 2024.

Record details

New Tech for Skin.

• Authors : Elias, Matthew J.; Ibrahimi, Omar A.

• Source: Dermatology Times. 2022, Vol. 43, Issue 11, pages. 2

Record details

Revance Provides an Update on DAXXIFY[R] Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results.

• Source: Business Wire. 2023.

Record details

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY[R] (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.

• Source: Business Wire. 2023.

Record details

New Frontiers in Laser, Light, Optical Devices.

• Authors : Jesitus, John

• Source: Dermatology Times. 2021, Vol. 42, Issue 11, pages. 2

Record details

Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment.

• Source: Business Wire. 2022.

Record details

Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY[TM] (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting.

• Source: Business Wire. 2022.

Record details

Revance Announces FDA Approval of DAXXIFY[TM] (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results.

• Source: Business Wire. 2022.

Record details

Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021.

• Source: Contify Life Science News. 2021.

Record details